Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

By M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore and 1 more. Journal of Clinical Oncology, 2009

1,547 citations recorded by the source corpus.

Subfields: Complementary and alternative medicine, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/b1571b872405037bc7d77e43380daa6e3a83baab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao
2. K. Kerr
3. N. Vasudev
4. B. Larrivée
5. M. Hellmann
6. C. Viallard
7. Andrew R Reynolds
8. Rakesh K. Jain

In Pulmonary and Respiratory Medicine

1. William Pao
2. B. Larrivée
3. C. Viallard
4. Rakesh K. Jain

Citations in the corpus

• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, methodology): “More data are needed to determine whether first-line use of gefitinib or erlotinib for patients with EGFR mutation improves OS.”
• Tumor angiogenesis and vascular normalization: alternative therapeutic targets (2017, result): “Similar results were observed in non-small cell lung cancer with the combination cisplatin/gemcitabine and bevacizumab [97] or in women bearing metastatic breast cancer with bevacizumab combined with”
• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Cisplatin/gemcitabine ± bevacizumab AVAiL [33] Improvement in PFS but not OS”
• Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) (2010, background): “The trial met its primary end point at the time of the first analysis, showing that PFS was significantly prolonged with bevacizumab compared with placebo (clinical cut-off 7 October 2006) [10].”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “A randomised phase III trial evaluating gemcitabine/cisplatin combination with or without bevacizumab demonstrated an ORR and modest PFS advantage, but no OS benefit [123].”